Compounded tirzepatide, the active ingredient in Mounjaro, is not reviewed by the FDA for safety, effectiveness, or quality before it reaches you. That’s the core issue. Unlike the brand-name product, which goes through rigorous manufacturing and testing, compounded versions are prepared by pharmacies with widely varying standards, and independent testing has already uncovered significant problems with some of these products.
That doesn’t mean every compounded vial is dangerous, but the risks are real and well-documented. Here’s what you need to know before deciding whether to use one.
The Legal Status Has Changed
Compounding pharmacies were initially allowed to produce tirzepatide because Mounjaro was on the FDA’s drug shortage list. Federal law permits pharmacies to compound copies of brand-name drugs during a shortage to help patients who can’t get the approved version. That legal window has closed. Tirzepatide no longer appears on the FDA’s drug shortage list, which means the legal basis for most compounding has disappeared.
Without the shortage designation, compounding pharmacies face strict limits. Under federal law, a 503A pharmacy (a traditional compounding pharmacy) cannot regularly produce drugs that are essentially copies of a commercially available product. A 503B outsourcing facility can only use bulk drug substances that either appear on a specific FDA-approved list or are tied to an active shortage. Tirzepatide currently appears on neither. The FDA has made this distinction publicly, signaling that compounded tirzepatide products now being sold may lack a lawful basis.
Purity and Potency Aren’t Guaranteed
When you fill a prescription for brand-name Mounjaro, the drug inside has been tested to confirm it contains the right amount of the right molecule, free of harmful contaminants. Compounded versions skip that process entirely. No federal agency checks what’s in the vial before it ships to you.
Independent lab testing has found concrete problems. A study analyzing compounded tirzepatide products that were combined with vitamin B12 (a common formulation sold by telehealth companies) discovered a previously unidentified impurity present at substantial levels. The impurity formed from a chemical reaction between tirzepatide and certain forms of B12. This wasn’t a rare defect in one batch; researchers described it as widespread across products obtained from various U.S. sources. The long-term effects of injecting this impurity are unknown because it was never studied in humans before showing up in people’s medications.
The FDA has also raised concerns about the specific forms of the drug being used. Some compounders have used salt forms of similar GLP-1 molecules, such as sodium or acetate versions, rather than the base form found in approved products. These are chemically different active ingredients. The FDA has stated it does not have information on whether these salt forms behave the same way in the body, and it is not aware of any lawful basis for their use in compounding.
Dosing Errors Are a Serious Risk
Brand-name Mounjaro comes in a pre-filled, single-dose auto-injector pen. You click a button, and it delivers a precise, pre-measured amount. Compounded tirzepatide typically comes in a multi-dose vial that requires you to draw up the correct amount using a syringe. This difference has led to dangerous mistakes.
The FDA has received reports of hospitalizations linked to dosing errors with compounded GLP-1 injectables. The pattern is consistent: patients accidentally draw up far more than intended. In documented cases, people administered 5 to 20 times the prescribed dose. The resulting adverse events included severe nausea and vomiting, fainting, dehydration, acute pancreatitis, and gallstones.
The errors aren’t always the patient’s fault. In multiple reports, healthcare providers themselves miscalculated doses when converting between milligrams, units, and milliliters. One provider meant to prescribe 0.25 milligrams (5 units) but wrote 25 units instead, giving a patient five times the intended dose. Another prescribed 20 units instead of 2 units, affecting three patients who each received ten times what they should have. In at least one case, a patient couldn’t get clear dosing instructions from a telemedicine provider and resorted to searching the internet, ultimately taking five times the correct amount.
These errors are built into the format. Drawing medication from a vial requires understanding concentration, volume, and syringe markings. Small misreadings produce large overdoses, especially with potent drugs like tirzepatide where the therapeutic dose is measured in fractions of a milligram.
Telehealth Marketing Under Scrutiny
Much of the compounded tirzepatide market runs through telehealth platforms that pair a brief online consultation with a shipped prescription. In March 2026, the FDA issued warning letters to 30 telehealth companies for making false or misleading claims about their compounded GLP-1 products. The most common violations included implying their products were the same as FDA-approved drugs and branding the medications with the telehealth company’s own name or trademark, which obscured where the drug was actually made.
This matters because the pharmacy behind the product is the single most important variable in compounded drug quality. When a telehealth site puts its own label on a vial without clearly identifying the compounding pharmacy, you lose the ability to verify who made your medication and whether that facility meets basic safety standards.
How to Vet a Compounding Pharmacy
If you’re considering compounded tirzepatide despite the risks, the quality of the pharmacy is the factor most within your control. Not all compounding pharmacies operate at the same level, and a few verification steps can help you distinguish between reputable operations and questionable ones.
- Check for NABP accreditation. The National Association of Boards of Pharmacy offers a compounding pharmacy accreditation that verifies alignment with USP standards, the recognized benchmarks for drug preparation quality. You can look up a pharmacy’s status through NABP’s online verification tool.
- Confirm state licensing. Every compounding pharmacy should hold an active license in your state. Your state board of pharmacy’s website will have a lookup tool to verify this.
- Ask about third-party testing. Reputable compounders test finished products for potency (whether the vial contains the amount listed on the label) and sterility (whether it’s free of microbial contamination). Ask whether they can provide a certificate of analysis for your specific batch.
- Identify the actual compounder. If you’re ordering through a telehealth platform, ask for the name and location of the pharmacy that compounds the product. If the company won’t tell you, that’s a red flag.
How Compounded Tirzepatide Compares to Brand-Name Mounjaro
The appeal of compounded tirzepatide is almost always cost. Brand-name Mounjaro can run over $1,000 per month without insurance, while compounded versions are often marketed at a fraction of that price. But the two products are not equivalent in any regulatory or quality-assurance sense.
Brand-name Mounjaro is manufactured under strict FDA oversight, with every batch tested for identity, potency, purity, and sterility before release. The drug’s safety profile has been established through large clinical trials involving thousands of patients. The auto-injector format eliminates dosing guesswork. Compounded tirzepatide has none of these safeguards. The active ingredient may differ in form, the concentration may not match the label, the product may contain unknown impurities, and the delivery method introduces a meaningful risk of overdose.
For people who genuinely cannot access or afford the approved product, compounded versions may feel like the only option. But the gap between the two is not just branding or price. It’s a difference in how much is known about what you’re injecting into your body and whether anyone has verified it before it reaches you.